Terms: = Colorectal cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Treatment
1466 results:
1. Genomic Alterations and Clinical Characterization in Chinese Patients with Metastatic colorectal cancer.
Zhang XH; Zhou JQ; Wei Q; Li J; Xu T; Bai CM; Zhou JF; Wang XC
Discov Med; 2024 Jul; 36(186):1477-1485. PubMed ID: 39054718
[TBL] [Abstract] [Full Text] [Related]
2. Hepatectomy versus systemic therapy for liver-limited braf V600E-mutated colorectal liver metastases: multicentre retrospective study.
Margonis GA; Wang JJ; Boerner T; Moretto R; Buettner S; Andreatos N; Gagnière J; Wagner D; Løes IM; Bergamo F; Pietrantonio F; Scartozzi M; Spallanzani A; Vincenzi B; Antoniou E; Pikoulis E; Sartore-Bianchi A; Stasinos G; Sasaki K; Pawlik TM; Orlandi A; Pella N; Fitschek F; Kaczirek K; Dupré A; Pozios I; Beyer K; Kornprat P; Aucejo FN; Burkhart R; Weiss MJ; Lønning PE; Poultsides G; Cremolini C; Kreis ME; D'Angelica M
Br J Surg; 2024 Jul; 111(7):. PubMed ID: 39051667
[TBL] [Abstract] [Full Text] [Related]
3. Current and Emerging treatment Paradigms in colorectal cancer: Integrating Hallmarks of cancer.
Salva de Torres C; Baraibar I; Saoudi González N; Ros J; Salva F; Rodríguez-Castells M; Alcaraz A; García A; Tabernero J; Élez E
Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000083
[TBL] [Abstract] [Full Text] [Related]
4. Novel drug resistance mechanisms and drug targets in braf-mutated peritoneal metastasis from colorectal cancer.
Lund-Andersen C; Torgunrud A; Kanduri C; Dagenborg VJ; Frøysnes IS; Larsen MM; Davidson B; Larsen SG; Flatmark K
J Transl Med; 2024 Jul; 22(1):646. PubMed ID: 38982444
[TBL] [Abstract] [Full Text] [Related]
5. Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or braf mutational status.
Zhang J; Zhou L; Zhao S; El-Deiry WS
Oncotarget; 2024 Jul; 15():424-438. PubMed ID: 38953895
[TBL] [Abstract] [Full Text] [Related]
6. Complete response of metastatic microsatellite-stable
Ree AH; Høye E; Esbensen Y; Beitnes AR; Negård A; Bernklev L; Tetlie LK; Fretland ÅA; Hamre HM; Kersten C; Hofsli E; Guren MG; Sorbye H; Nilsen HL; Flatmark K; Meltzer S
Oncoimmunology; 2024; 13(1):2372886. PubMed ID: 38952672
[TBL] [Abstract] [Full Text] [Related]
7. Progress in clinical diagnosis and treatment of colorectal cancer with rare genetic variants.
Chen S; Gu J; Wu K; Zhao X; Lu Y
Cancer Biol Med; 2024 Jun; 21(6):473-83. PubMed ID: 38940668
[TBL] [Abstract] [Full Text] [Related]
8. Radiomic Parameters for the Evaluation of Response to treatment in Metastatic colorectal cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial.
Martinelli E; Ciardiello D; Martini G; Napolitano S; Del Tufo S; D'Ambrosio L; De Chiara M; Famiglietti V; Nacca V; Cardone C; Avallone A; Cremolini C; Pietrantonio F; Maiello E; Granata V; Troiani T; Cappabianca S; Ciardiello F; Nardone V; Reginelli A
Clin Drug Investig; 2024 Jul; 44(7):541-548. PubMed ID: 38886336
[TBL] [Abstract] [Full Text] [Related]
9.
Imai T; Shoji H; Hirano H; Matsuguma K; Awatsu T; Hirose T; Okita N; Takashima A; Kato K
CNS Oncol; 2024 Jun; 13(1):2347824. PubMed ID: 38869444
[TBL] [Abstract] [Full Text] [Related]
10. Comparison of genomic profiling of patient-matched primary colorectal and surgical resected distant metastatic (stage IV) colorectal carcinoma for drug actionability.
Jan YH; Lu CT; Lam AK
Hum Pathol; 2024 Jul; 149():21-28. PubMed ID: 38862093
[TBL] [Abstract] [Full Text] [Related]
11. Rechallenge with Anti-EGFR treatment in RAS/braf wt Metastatic colorectal cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group.
Salgado Fernández M; Reboredo López M; Covela Rúa M; Candamio S; González-Villarroel P; Sánchez-Cousido LF; Graña B; Carral-Maseda A; Cameselle-García S; Varela Pose V; Gallardo-Martín ME; Martínez-Lago N;
Target Oncol; 2024 Jul; 19(4):565-573. PubMed ID: 38780742
[TBL] [Abstract] [Full Text] [Related]
12. Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer.
Wang W; Huang Y; Kong J; Lu L; Liao Q; Zhu J; Wang T; Yan L; Dai M; Chen Z; You J
Clin Transl Oncol; 2024 Aug; 26(8):1976-1987. PubMed ID: 38777950
[TBL] [Abstract] [Full Text] [Related]
13. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.
Ambrosini M; Rousseau B; Manca P; Artz O; Marabelle A; André T; Maddalena G; Mazzoli G; Intini R; Cohen R; Cercek A; Segal NH; Saltz L; Varghese AM; Yaeger R; Nusrat M; Goldberg Z; Ku GY; El Dika I; Margalit O; Grinshpun A; Murtaza Kasi P; Schilsky R; Lutfi A; Shacham-Shmueli E; Khan Afghan M; Weiss L; Westphalen CB; Conca V; Decker B; Randon G; Elez E; Fakih M; Schrock AB; Cremolini C; Jayachandran P; Overman MJ; Lonardi S; Pietrantonio F
Ann Oncol; 2024 Jul; 35(7):643-655. PubMed ID: 38777726
[TBL] [Abstract] [Full Text] [Related]
14. Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy.
González NS; Marchese PV; Baraibar I; Ros J; Salvà F; Rodríguez M; Salvà C; Vaghi C; Alcaraz A; García A; Tabernero J; Élez E
Expert Opin Investig Drugs; 2024 Jun; 33(6):613-625. PubMed ID: 38775361
[TBL] [Abstract] [Full Text] [Related]
15. Deep neural network for the prediction of KRAS, NRAS, and braf genotypes in left-sided colorectal cancer based on histopathologic images.
Li X; Chi X; Huang P; Liang Q; Liu J
Comput Med Imaging Graph; 2024 Jul; 115():102384. PubMed ID: 38759471
[TBL] [Abstract] [Full Text] [Related]
16. Molecular Deciphering of colorectal cancer: Exploring Molecular Classifications and Analyzing the Interplay among Molecular Biomarkers MMR/MSI, KRAS, NRAS, braf and CDX2 - A Comprehensive Literature Review.
Ilie-Petrov AC; Cristian DA; Diaconescu AS; Chitul A; Blajin A; Popa A; Mandi DM; Negreanu R; Vieru C; Vrîncianu R; Ardeleanu CM
Chirurgia (Bucur); 2024 Apr; 119(2):136-155. PubMed ID: 38743828
[No Abstract] [Full Text] [Related]
17. Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in
Zhang H; Read A; Cataisson C; Yang HH; Lee WC; Turk BE; Yuspa SH; Luo J
Sci Signal; 2024 May; 17(836):eadd5073. PubMed ID: 38743809
[TBL] [Abstract] [Full Text] [Related]
18. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/braf wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
Wang DS; Ren C; Li SS; Fong WP; Wu XJ; Xiao J; Li BK; Zheng Y; Ding PR; Chen G; Qiu MZ; Wang ZQ; Wang FH; Luo HY; Wang F; Wang XZ; Wang LY; Xie DJ; Chen T; Li LR; Lu ZH; Zhai XH; Liu TS; Yuan Y; Chen JQ; Tan Q; Pan ZZ; Wan DS; Zhang R; Yuan YF; Xu RH; Li YH
PLoS Med; 2024 May; 21(5):e1004389. PubMed ID: 38728364
[TBL] [Abstract] [Full Text] [Related]
19. The Relationship of Microsatellite Instability with braf and p53 Mutations and Histopathological Parameters in colorectal Adenocarcinoma.
Gündoğar Ö; Bektaş S; Yıldırım E; Gönüllü D
Ann Ital Chir; 2024; 95(2):181-191. PubMed ID: 38684491
[TBL] [Abstract] [Full Text] [Related]
20. First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial.
Ree AH; Šaltytė Benth J; Hamre HM; Kersten C; Hofsli E; Guren MG; Sorbye H; Johansen C; Negård A; Bjørnetrø T; Nilsen HL; Berg JP; Flatmark K; Meltzer S
Br J Cancer; 2024 Jun; 130(12):1921-1928. PubMed ID: 38664577
[TBL] [Abstract] [Full Text] [Related]
[Next]
